Table 3 Clinical and laboratory findings dependent on TKTL1 expression status

Median age (n = 33): 61 years

63

59

p = 0.89

Clinical tumour stage

uN negative n = 5 (29%)

uN negative n = 5 (31%)

p = 1.0

uN positive n = 12 (71%)

uN positive n = 11 (69%)

Pathological tumour stage (n = 32)

ypT0N0 n = 1

ypT0N0 n = 2

p = 0.69

ypT1-2N0 n = 6

ypT1-2N0 n = 6

ypT3-4N0 n = 6

ypT3-4N0 n = 2

ypTanyN+ n = 4

ypTanyN+ n = 5

CEA (median)

2.1

4.25

p = 0.074

CA 19-9

10

23

p = 0.18

VEGFR1 (median)

0.4125; n = 10

0.1034; n = 16

p = 0.19

VEGFR2 (median)

0.4413; n = 16

0.8241; n = 16

p = 0.11

Survivin (n = 30) (median)

6.4; n = 17

8.5; n = 13

p = 0.081

KRAS mutated (n = 14/33)

n = 6 (35%)

n = 8 (50%)

p = 0.49

Loss of PTEN (n = 2/30)

n = 1/16 (6%)

n = 1/14 (7%)

p = 1.0

Local recurrence

n = 0 (0%)

n = 2 (12.5%)

p = 0.22

Metastasis during follow up

n = 1 (6%)

n = 9 (56%)

p = 0.0024

Median DFS ∞ (months)

39

23

p = 0.017

Death

n = 2 (12%)

n = 4 (25%)

p = 0.39

Median Survival (months)

39

26

p = 0.26